

# MAGLUMI CA 19-9 (CLIA)

REF

130201011M



100



**Shenzhen New Industries  
Biomedical Engineering Co., Ltd**  
4F, Wearnes Tech Bldg,  
Science & Industry Park,  
Nanshan, Shenzhen, 518057 CHINA  
Tel. + 86-755-86028224  
Fax. + 86-755-26654850

EC REP

**Lotus Global Co., Ltd**  
15 Alexandra Road  
London  
NW8 0DP  
UK  
Tel. + 44-20-75868010  
Fax. + 44-20-79006187



**FOR PROFESSIONAL USE ONLY**  
Store at 2-8°C



COMPLETELY READ THE INSTRUCTIONS BEFORE  
PROCEEDING



## SYMBOLS EXPLANATIONS

EC REP

Authorized Representative in Europe



Manufacturer



Attention. See Instructions For Use

CONT

Contents of kit

IVD

In vitro diagnostic medical device  
(In vitro diagnostic use)

LOT

Lot number

REF

Catalogue Code



Expiry date (Use by...)



Temperature limitation  
(store at 2-8°C)



Number of tests



Keep away from direct sunlight



Keep upright for storage

## INTENDED USE

The kit has been designed for the quantitative determination of Cancer Antigen 19-9 (CA19-9) in human serum.

The method can be used for samples over the range of 0-1,000 IU/ml.

The test has to be performed on the MAGLUMI chemiluminescence immunoassay (CLIA) fully auto analyzer (Including MAGLUMI 1000, MAGLUMI 2000, MAGLUMI 2000 Plus and new developed models).

## SUMMARY AND EXPLANATION OF THE TEST

The monoclonal antibody 1116NS-19-9 recognizes the epitope sialy-lacto-N-fucopentose II, which is closely related to the Lewis blood group antigen. This epitope was found both on glycolipids and mucin-like glycoproteins of tumors.

CA19-9 assay levels are elevated in patients with pancreatic tumors or with hepatic, gastric and colorectal tumors and are useful for follow-up and therapeutic monitoring.

## PRINCIPLE OF THE TEST

Sandwich immunoluminometric assay;

Use an anti-CA19-9 monoclonal antibody to label ABEI. Sample, Calibrator or Control with buffer and magnetic microbeads coated with anti-CA19-9 are mixed thoroughly and incubated at 37°C, forming a sandwich; after sediment in a magnetic field, decant the supernatant, then cycle washing for 1 time. Then add ABEI Label, incubation and washing for the 2nd time. Subsequently, the starter reagents are added and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as RLU within 3 seconds and is proportional to the concentration of CA19-9 present in controls or samples.

CONT

## KIT COMPONENTS

### Material Supplies

Reagent Integral for 100 determinations	
<b>Nano magnetic microbeads:</b> TRIS buffer, 1.2%(W/V), 0.2%NaN <sub>3</sub> , coated with anti-CA19-9 monoclonal	2.5ml
<b>Calibrator Low:</b> bovine serum, 0.2%NaN <sub>3</sub> .	2.5ml
<b>Calibrator High:</b> bovine serum, 0.2%NaN <sub>3</sub> .	2.5ml
<b>Buffer:</b> bovine serum, 0.2%NaN <sub>3</sub>	12.5ml
<b>ABEI Label:</b> anti-CA19-9 monoclonal antibody labeled ABEI contains BSA, 0.2%NaN <sub>3</sub> .	22.5ml
<b>Diluent:</b> 0.9%NaCl	25ml
All reagents are provided ready-to-use.	

### Reagent Vials in kit box

<b>Internal Quality Control:</b> containing BSA, 0.2%NaN <sub>3</sub> . (target value refer to Quality Control Information date sheet)	2.0ml
--	-------

### Accessories Required But Not Provided

MAGLUMI Reaction Module	REF: 630003
MAGLUMI Starter 1+2	REF: 130299004M
MAGLUMI Wash Concentrate	REF: 130299005M
MAGLUMI Light Check	REF: 130299006M



### Preparation of the Reagent Integral



Before the sealing is removed, gentle and careful horizontal

shaking of the Reagent Integral is essential (avoid foam formation!) Remove the sealing and turn the small wheel of the magnetic microbeads compartment to and fro, until the color of the suspension has changed into brown. Place the Integral into the reagent area and let it stand there for 30 min. During this time, the magnetic microbeads are automatically agitated and completely resuspended.

**Do not interchange integral component from different reagents or lots!**

#### Storage and Stability

- Sealed: Stored at 2-8°C until the expiry date.
- Opened: Stable for 4 weeks. To ensure the best kit performance, it is recommended to place opened kits in the refrigerator if it's not going to be used on board during the next 12 hours.



## CALIBRATION AND TRACEABILITY

### 1) Traceability

To perform an accurate calibration, we have provided the test calibrators standardized against SNIBE internal reference substance.

Calibrators in the Reagent Kit are from Bidesign.

### 2) 2-Point Recalibration

Via the measurement of calibrators, the predefined master curve is adjusted (recalibrated) to a new, instrument-specific measurement level with each calibration.

### 3) Frequency of Recalibration

- After each exchange of lot (Reagent Integral or Starter Reagents).
- Every 2 weeks and/or each time a new Integral is used (recommendation).
- After each servicing of the MAGLUMI Fully Auto analyzer.
- If controls are beyond the expected range.

## SPECIMEN COLLECTION AND PREPARATION

Sample material: serum

Collect samples using standard procedures.

Store at 2-8°C: 12 hours, for longer storage periods: freeze to below -20°C.

Avoid repeated freezing and thawing cycles, stored samples should be thoroughly mixed prior to use (Vortex mixer).

Please ask local representative of SNIBE for more details if you have any doubt.

### Vacuum Tubes

- (a) Blank tubes are recommended type for collecting samples.
- (b) Please ask SNIBE for advice if special additive must be used in sample collecting.

### Specimen Conditions

- Do not use specimens with the following conditions:
  - (a) heat-inactivated specimens;
  - (b) Cadaver specimens or body fluids other than human serum;
  - (c) Obvious microbial contamination.
- Use caution when handling patient specimens to prevent cross contamination. Use of disposable pipettes or pipette tips is recommended.
- Inspect all samples for bubbles. Remove bubbles with an applicator stick prior to analysis. Use a new applicator stick for

each sample to prevent cross contamination.

- Serum specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.

### Preparation for Analysis

- Patient specimens with a cloudy or turbid appearance must be centrifuged prior to testing. Following centrifugation, avoid the lipid layer (if present) when pipetting the specimen into a sample cup or secondary tube.
- Specimens must be mixed **thoroughly** after thawing by **low** speed vortexing or by gently inverting, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results. Multiple freeze-thaw cycles of specimens should be avoided.
- All samples (patient specimens or controls) should be tested within 3 hours of being placed on board the MAGLUMI System. Refer to the SNIBE service for a more detailed discussion of onboard sample storage constraints.


### Storage

- If testing will be delayed for more than 8 hours, remove serum or plasma from the serum or plasma separator, red blood cells or clot. Specimens removed from the separator gel, cells or clot may be stored up to 12 hours at 2-8°C.
- Specimens can be stored up to 30 days frozen at -20°C or colder.

### Shipping

Before shipping specimens, it is recommended that specimens be removed from the serum or plasma separator, red blood cells or clot. When shipped, specimens must be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens must be shipped frozen (dry ice). Do not exceed the storage time limitations identified in this section of the package insert.

## WARNING AND PRECAUTIONS FOR USERS



- For use in *IN-VITRO* diagnostic procedures only.
- Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

### Safety Precautions

**CAUTION:** This product requires the handling of human specimens.

- The calibrators in this kit are prepared from bovine serum products. However, because no test method can offer complete assurance that HIV, Hepatitis B Virus or other infectious agents are absent; these reagents should be considered a potential biohazard and handled with the same precautions as applied to any serum or plasma specimen.
- All samples, biological reagents and materials used in the assay must be considered potentially able to transmit infectious agents. They should therefore be disposed of in accordance with the prevailing regulations and guidelines of the agencies holding jurisdiction over the laboratory, and the regulations of each country. Disposable materials must be incinerated; liquid waste must be decontaminated with sodium hypochlorite at a final concentration of 5% for at least half an hour. Any materials to be reused must be

autoclaved using an overkill approach (USP 24, 2000, p.2143). A minimum of one hour at 121°C is usually considered adequate, though the users must check the effectiveness of their decontamination cycle by initially validating it and routinely using biological indicators.

- It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the OSHA Standard on Blood borne Pathogens 13. Biosafety Level 214 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- This product contains Sodium Azide; this material and its container must be disposed of in a safe way.
- Safety data sheets are available on request.

#### Handling Precautions

- Do not use reagent kits beyond the expiration date.
- Do not mix reagents from different reagent kits.
- Prior to loading the Reagent Kit on the system for the first time, the microbeads requires mixing to re-suspend microbeads that have settled during shipment.
- For microbeads mixing instructions, refer to the KIT COMPONENTS, Preparation of the Reagent Integral section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and sample.
- Over time, residual liquids may dry on the kit surface; please pay attention to the silicon film still exists on the surface of the kit.
- For a detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

#### TEST PROCEDURE

To ensure proper test performance, strictly adhere to the operating instructions of the MAGLUMI Fully Auto analyzer. Each test parameter is identified via a RFID tag on the Reagent Integral. For further information please refer to the MAGLUMI Chemiluminescence Analyzer Operating Instructions.

50µl	Sample, calibrator or controls
+100µl	Buffer
+20µl	Nano magnetic microbeads
10 min	Incubation
400µl	Cycle washing
+200µl	ABEI Label
10 min	Incubation
400µl	Cycle washing
3 s	Measurement

#### DILUTION

Samples with concentrations above the measuring range can be diluted. After manual dilution, multiply the result by the dilution factor. After dilution by the analyzers, the analyzer software automatically takes the dilution into account when calculating the sample concentration.

Availability of sample dilution by analyzer please refers to the MAGLUMI analyzer user software program. Dilution settings please follow MALGUMI analyzer operating instructions.

#### QUALITY CONTROL

- Observe quality control guidelines for medical laboratories
- Use suitable controls for in-house quality control. Controls should be run at least once every 24 hours when the test is in use, once per reagent kit and after every calibration. The control intervals should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined ranges. Each laboratory should establish guidelines for corrective measures to be taken if values fall outside the range.

#### LIMITATIONS OF THE PROCEDURE

##### 1) Limitations

Tumor patients may exhibit CA19-9 assay values below the cut-off. Elevated levels are observed in patients with cystic fibrosis and severe benign liver disorders. Therefore CA 19-9 assay values may only be interpreted in context with the clinical picture and other diagnostic procedures.

##### 2) Interfering Substances

No interference with test results is seen by concentrations of bilirubin < 0.125mg/ml, hemoglobin < 16mg/dl or triglycerides < 12.5 mg/ml.

##### 3) HAMA

Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

##### 4) High-Dose Hook

No high-dose hook effect was seen for CA19-9 concentrations up to 10,000IU/ml.

#### RESULTS

##### 1) Calculation of Results

The analyzer automatically calculates the CA19-9 concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in IU/ml. For further information please refer to the MAGLUMI Chemiluminescence Analyzer Operating Instructions.

##### 2) Interpretation of Results

- Results of study in clinical centers with group of individuals, 95% of the results were < 37IU/ml.
- Results may differ between laboratories due to variations in population and test method. If necessary, each laboratory should establish its own reference range.

#### PERFORMANCE CHARACTERISTICS

##### 1) Precision

Intra-assay coefficient of variation was evaluated on 3 different levels of control serum repeatedly measured 20 times in the same run, calculating the coefficient of variation.

Intra-assay precision			
Control	Mean(IU/ml)	SD(IU/ml)	CV%
Level 1	30.74	2.05	6.04
Level 2	69.32	3.76	5.42
Level 3	184.67	8.79	4.76

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 21 times, calculating the coefficient of variation.

Inter-assay precision			
Control	Mean(IU/ml)	SD(IU/ml)	CV%
Level 1	28.04	2.61	9.21
Level 2	75.69	7.29	9.64
Level 3	188.35	16.04	8.52

##### 2) Analytical Sensitivity

The sensitivity is defined as the concentration of CA19-9 equivalent to the mean RLU of 20 replicates of the zero standard plus two standard deviations corresponding to the concentration from the standard curve. The sensitivity is typically less than 2.5IU/ml.

##### 3) Specificity

The specificity of the CA19-9 assay system was assessed by measuring the apparent response of the assay to various potentially cross reactive analytes.

Compound	Concentration	Cross reactivity
CA125	400IU/ml	0.8%
CA15-3	400IU/ml	0.5%
CA72-4	400IU/ml	0.6%

#### 4) Recovery

Consider calibrator high of known concentration as a sample, dilute it by 1:2 ratios with diluents, and measure its diluted concentration for 10 times. Then calculate the recovery of measured concentration and expected concentration. The recovery should be within 90% -110%.

Expected	Mean Measuring	Recovery
254.461IU/ml	249.723IU/ml	98%

#### 5) Linearity

Use CA19-9 calibrator to prepare the six-point standard curve, measuring all points' RLU except point A, and then do four-parameter linear fitting in double logarithm coordinate, the absolute linear correlation coefficient(r) should be bigger than 0.9800.

Calibrator Point	Concentration IU/ml	Absolute linear correlation coefficient (r)
A	0	
B	10	r=0.9834
C	50	
D	100	
E	200	
F	500	

#### 6) Method comparison

A comparison of MAGLUMI CA19-9(y) with a commercially available CA19-9 test(x) using clinical samples gave the following correlations (IU/ml):

Linear regression

$$y = 0.97x + 18.$$

$$r = 0.962$$

$$S_{y,x} = 21.37$$

Number of samples measured: 163

The sample concentrations were between 9.01 and 3416.24 IU/ml.

#### REFERENCES

1. Bartoloni C, Guidi L, Baroni R, Tricerri A, Barone C, Garufi C, Gaambassi G. Longitudinal Study of CA19-9 And CEA in Gastrointestinal Cancer Patients at Different Stages. *J Tumor Marker Oncol* 19-90;5(4):351-362.
2. Maggino T, Gadducci A. Serum markers as prognostic factors in epithelial ovarian cancer: an overview. *Eur J Gynaecol Oncol*, 2000,21(1):6466-6468.
3. Oberti F, Valsesia E, Pilette C, et al. Non-invasive diagnosis of hepatic fibrosis or cirrhosis. *Gastroenterology*, 19-97, 113: 1609-1616.
4. Johansson C; Evaluation of Serum CA125, CA19-9 and CA15-3 Detection in Ovarian Tumors; college paper—2006 /5.
5. Kawa S; Clinical Assessment of the Usefulness of Determination of Serum Levels of Four Tumor Markers (Carbohydrate Antigens CEA, CA19-9, CA125, CA15-3) in patients with Lung Cancer; immunity magazine--2004/1.
6. Hasebe O; Clinical Significance of Testing Serum Marker CA125, CA19-9, CA153 for Malignant Tumor of Uterus tumour--2004/3.
7. Glimelius B; Diagnostic significance of multiple tumor marker detection in hydropleuritis; clinic tumor-2004/6.

8. Hasholzner U; Diagnostic Significance of Measuring CEA, CA19-9, CA125 and CA15-3 for Patients with Lung Cancer clinic--2001/5.
9. Hasholzner U; Significance on evaluation of extent of measuring CA125, CA19-9,  $\beta$ -HCG for patients with breast cancer; laser magazine--2005/6.
10. Micalo; Adipose tissue concentrations of persistent organic pollutants and the risk of prostate cancer. *J Occup Environ Med*. 2006 Jul;48(7):700-7.
11. Stieber P; Expression of Serum TPS and CA19-9 in Patients with Breast Cancer and Its Clinical Significance; college paper-2004/2.
12. Reiter W; Diagnosis Value of Combination Assay of Three Tumor Markers, CA19-9 and CA242 in Lung Cancer; modern tumor medicine--2005/2.
13. Hatake K, Takeuchi I. Comparison of CA 19-9 with Other Tumor Markers in the Diagnosis of Cancer of the Pancreas. *Pancreas* 19-94;9(6):720-724.